Christopher Smith Jeff Van-Drew Denmark state New Jersey reports Citi Southern Christopher Smith Jeff Van-Drew Denmark state New Jersey

NOAA: New Jersey wind farm may 'adversely affect,' not kill whales

Reading now: 207
www.fox29.com

(File Photo)  ATLANTIC CITY, N.J. - New Jersey's first offshore wind farm may "adversely affect" whales and other marine mammals, but its construction, operation and eventual dismantling will not seriously harm or kill them, a federal scientific agency said.The National Oceanic and Atmospheric Administration issued a report Tuesday evaluating an analysis by the U.S.

Bureau of Ocean Energy Management of the Ocean Wind I project to be built off the southern New Jersey coast.NOAA's final biological opinion examined BOEM's research, and took into account "the best scientific and commercial data available."NOAA determined the project by Danish wind power company Orsted "is likely to adversely affect, but is not likely to jeopardize, the continued existence of any species" of endangered whales, sea turtles and other animals.

Nor is it likely to "destroy or adversely modify any designated critical habitat."The report comes as opposition to offshore wind projects on the U.S.

East Coast is growing, fueled by a thus-far unproven narrative that ocean floor preparation work for offshore wind farms is hurting or killing whales.

Read more on fox29.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

Health News - Peter Marks - World’s 1st RSV vaccine approved in U.S. for adults aged 60 and up - globalnews.ca - Usa - Canada
globalnews.ca
54%
821
World’s 1st RSV vaccine approved in U.S. for adults aged 60 and up
respiratory syncytial virus (RSV) was approved by the U.S. Food and Drug Administration (FDA) on Wednesday.The Arexvy vaccine, made by GlaxoSmithKline (GSK), was approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, according to an FDA release.“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in the statement.“Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”RSV infection is a major cause of lower respiratory illness, particularly among infants, young children and older adults.Canada currently does not have a vaccine for RSV.However, Health Canada has accepted and is reviewing Pfizer Canada’s bivalent RSV vaccine for babies under six months and individuals aged 60 and above, the pharmaceutical company said in a statement on April 14.The health agency is also reviewing GSK’s RSV vaccine for adults 60 years of age and older.Several companies are creating RSV vaccines but Pfizer and rival GSK are furthest along.  The competing vaccines are made somewhat differently but each proved strongly effective, especially against serious disease.For most healthy people, RSV is a cold-like nuisance.For the very young, the elderly and people with certain health problems, it can be serious, even life-threatening.
DMCA